Advanced in Metastatic Brain Tumor

Dr. Toni K. Choueiri

Oncology
Dana-Farber Cancer Institute, Inc.
20 Prospect St, Suite 2, 
Milford, MA 
Accepting New Patients
Offers Telehealth
Advanced in Metastatic Brain Tumor
Dana-Farber Cancer Institute, Inc.
20 Prospect St, Suite 2, 
Milford, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Toni Choueiri is an Oncologist in Milford, Massachusetts. Dr. Choueiri is rated as an Advanced provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Choueiri is currently accepting new patients.

His clinical research consists of co-authoring 806 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Metastatic Brain Tumor.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
20 Prospect St, Suite 2, Milford, MA 01757
Other Locations
DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, MK-6482
Study Phase: Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab
Study Phase: Phase 2
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Drug
Study Drug: Oral NKT2152
Study Phase: Phase 1/Phase 2
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

795 Total Publications

Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2025
Similar Doctors
Elite in Metastatic Brain Tumor
Dr. Priscilla Brastianos
Hematology Oncology | Oncology
Elite in Metastatic Brain Tumor
Dr. Priscilla Brastianos
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (28.4 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Priscilla Brastianos is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Brastianos is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Brain Tumor, Metastatic Brain Tumor, Melanoma, and Posterior Fossa Tumor.

Elite in Metastatic Brain Tumor
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology
Elite in Metastatic Brain Tumor
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (25.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Reardon is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Reardon is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Reardon is currently accepting new patients.

Distinguished in Metastatic Brain Tumor
Dr. Nancy U. Lin
Hematology Oncology | Hematology | Oncology
Distinguished in Metastatic Brain Tumor
Dr. Nancy U. Lin
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (25.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nancy Lin is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Lin is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Breast Cancer, Brain Tumor, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer. Dr. Lin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Choueiri's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile